Axsome Therapeutics (AXSM) Accumulated Expenses (2022 - 2025)
Historic Accumulated Expenses for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $139.5 million.
- Axsome Therapeutics' Accumulated Expenses rose 10281.97% to $139.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.5 million, marking a year-over-year increase of 10281.97%. This contributed to the annual value of $74.0 million for FY2024, which is 5831.14% up from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' Accumulated Expenses is $139.5 million, which was up 10281.97% from $118.2 million recorded in Q2 2025.
- Axsome Therapeutics' Accumulated Expenses' 5-year high stood at $139.5 million during Q3 2025, with a 5-year trough of $2.7 million in Q1 2022.
- In the last 4 years, Axsome Therapeutics' Accumulated Expenses had a median value of $46.7 million in 2023 and averaged $54.2 million.
- As far as peak fluctuations go, Axsome Therapeutics' Accumulated Expenses surged by 101579.42% in 2023, and later skyrocketed by 5831.14% in 2024.
- Axsome Therapeutics' Accumulated Expenses (Quarter) stood at $26.5 million in 2022, then skyrocketed by 75.98% to $46.7 million in 2023, then soared by 58.31% to $74.0 million in 2024, then soared by 88.6% to $139.5 million in 2025.
- Its Accumulated Expenses stands at $139.5 million for Q3 2025, versus $118.2 million for Q2 2025 and $95.8 million for Q1 2025.